Polyrizon Ltd. (NASDAQ: PLRZ) shares on an upward trajectory on the US stock today following the announcement of advancements in its patent application process. At the latest market check, PLRZ stock was trading at $2.10, reflecting a significant rise of 28.12%.
Key Patent Application Published by USPTO
Polyrizon has officially disclosed the publication of a national phase patent application by the United States Patent and Trademark Office (USPTO). The patent encompasses two of the company’s foundational platform technologies: Capture and Contain (C&C), a nasal blocker technology, and Trap and Target (T&T), which is designed for advanced nasal drug delivery. These technologies represent Polyrizon’s ongoing efforts to deliver innovative solutions for protection and treatment via the nasal cavity.
Innovative Technologies: Protection and Drug Delivery
A unique 3D polymeric network created to best stick to the nasal mucosa is used by the Capture and Contain (C&C) platform. This creates a physical barrier that traps airborne biological threats, such as allergens, viruses, and molds, effectively preventing them from entering the body.
Additionally, the Trap and Target (T&T) platform enhances drug delivery by ensuring a prolonged residence time in the nasal cavity. Because of its direct interaction with mucosal tissues, this method guarantees precise and extremely efficient drug administration. Both platforms are tailored to meet the needs of various medical applications, improving therapeutic outcomes.
Strategic Manufacturing Partnership for PL-14 Trial
Polyrizon has also recently expanded its strategic capabilities through a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a leading European-based GMP manufacturer. This collaboration will provide Clinical Trial Material (CTM) for PLRZ’s PL-14 allergy blocker, slated for a clinical trial in 2025.
The agreement ensures a reliable and compliant manufacturing source for the trial, which will evaluate the safety and efficacy of PL-14 in treating allergies. This partnership bolsters Polyrizon’s readiness for its upcoming trial, aligning with regulatory standards in both the USA and Europe.
